Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Abgenix, Inc. (NasdaqNM:ABGX)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials | Reports
Location
6701 Kaiser Drive
Fremont, CA 94555
Phone: (510) 608-6500
Fax: (510) 608-6511
Email: invest@abgenix.com
Employees (last reported count): 174
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Index Membership
 ·Nasdaq 100
Ownership
·Insider and 5%+ Owners: 25%
·Over the last 6 months:
 · 2 insider buys; 27.0K shares (0.1% of insider shares)
 · 7 insider sells; 146.0K shares
  (0.7% of insider shares)
·Institutional: 76% (101% of float)
(402 institutions)
·Net Inst. Buying: 5.83M shares (+8.21%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Abgenix, Inc. is a biopharmaceutical company that develops and intends to commercialize antibody therapeutic products for the treatment of a variety of disease conditions, including transplant-related diseases, inflammatory and autoimmune disorders, cardiovascular disease, infectious diseases and cancer. The Company has three antibody product candidates that are currently in clinical trials. These are ABX-IL8, ABX-EGF, and ABX-CBL. ABX-IL8 is the Company's fully human antibody candidate for the treatment of psoriasis and rheumatoid arthritis. ABX-EGF is the Company's fully human antibody candidate for the treatment of a variety of cancers. ABX-CBL is an in-licensed mouse antibody, for the treatment of a transplant-related disease known as graft versus host disease.
More from Market Guide: Expanded Business Description

Financial Summary
Abgenix, Inc. develops and intends to commercialize antibody therapeutic products for the treatment of a variety of disease conditions. For the six months ended 6/30/01, revenues rose 64% to $30.5 million. Net loss totaled $22.4 million, up from $5.8 million. Revenues reflect a $9 million proprietary product development fee under agreements. Higher loss reflects an increase in personnel expenses and higher amortization of goodwill charges.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

R. Scott Greer, 42
Chairman, CEO
$616K$27.4M
Raymond Withy, Ph.D., 45
Pres, COO
332K15.0M
Kurt Leutzinger, 49
CFO
337K3.0M
C. Geoffrey Davis, Ph.D., 49
CSO
327K--  
Susan Thorner, 52
VP, Gen. Counsel, Sec.
--  --  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:ABGXAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-Mar-2001
$15.313
Recent Price$29.97 
52-Week High
on 3-Nov-2000
$94.875
Beta2.32 
Daily Volume (3-month avg)1.43M
Daily Volume (10-day avg)1.51M
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y]
52-Week Change-62.4%
52-Week Change
relative to S&P500
-49.5%
Share-Related Items
Market Capitalization$2.58B
Shares Outstanding86.2M
Float64.6M
Dividends & Splits
Annual Dividendnone 
Last Split: 2 for 1 on 10-July-2000
Per-Share Data
Book Value (mrq)$9.79 
Earnings (ttm)-$0.29 
Earnings (mrq)-$0.17 
Sales (ttm)$0.81 
Cash (mrq)$6.68 
Valuation Ratios
Price/Book (mrq)3.06 
Price/EarningsN/A 
Price/Sales (ttm)36.76 
Income Statements
Sales (ttm)$71.4M
EBITDA (ttm)-$18.9M
Income available to common (ttm)-$25.4M
Profitability
Profit Margin (ttm)-35.6%
Operating Margin (ttm)-35.6%
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-3.17%
Return on Equity (ttm)-3.35%
Financial Strength
Current Ratio (mrq)24.32 
Debt/Equity (mrq)0 
Total Cash (mrq)$575.4M
Short Interest
As of 8-Aug-2001
Shares Short1.80M
Percent of Float2.8%
Shares Short
(Prior Month)
2.08M
Short Ratio1.16 
Daily Volume1.55M
See Profile Help for a description of each item above;   K = thousands;   M = millions;   B = billions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.